Literature DB >> 9842558

Tarsal patch-flap for orbital implant exposure.

C N Soparkar1, J R Patrinely.   

Abstract

The authors determine the efficacy of a new technique, the tarsal patch-flap, in the management of postenucleation and postevisceration porous orbital implant exposures that are recalcitrant to other surgical approaches. All patients treated during a 30-month period with recurrent orbital implant exposures who failed at least one surgical attempt at defect closure were treated using a tarsal patch-flap, a fornix-based tarsoconjunctival flap from the upper eyelid. Eight patients, six after enucleation and two after evisceration, were treated with a tarsal patch-flap. Five implants were porous polyethylene and three were hydroxyapatite. The defect size ranged from 4 mm to 12 mm (largest dimension). All eight patients have maintained closure of their defects for a mean follow-up of 13.8 months (range, 4-30 months). The vascularized tarsal patch-flap provides an excellent alternative surgical approach to the management of recurrent orbital implant exposures recalcitrant to Tenon-conjunctival advancement and autologous fascia grafting.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9842558     DOI: 10.1097/00002341-199811000-00002

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  3 in total

1.  Autogenous temporalis fascia patch graft for porous polyethylene (Medpor) sphere orbital implant exposure.

Authors:  M S Sagoo; J M Olver
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

2.  Treatment of intractable orbital implant exposure with a large conjunctival defect by secondary insertion of the implant after preceding dermis fat graft.

Authors:  Hyun Kyung Kim; Tae Yoon La
Journal:  Int J Ophthalmol       Date:  2013-04-18       Impact factor: 1.779

3.  Indications and results in anophthalmic socket reconstruction using dermis-fat graft.

Authors:  Orapan Aryasit; Passorn Preechawai
Journal:  Clin Ophthalmol       Date:  2015-05-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.